News AZ's Lynparza becomes first PARP drug approved in breast can... Lynparza first in class approved in breast cancer
News Clovis PARP drug gets fast US review in new ovarian cancer u... Impressed by survival data, FDA hastens review in expanded patient group
News Tesaro gets European approval on Zejula, set to challenge AZ Tesaro's PARP drug approved in wider ovarian cancer population
News MicroRNA diagnostic could be big advance in ovarian cancer AI blood test achieves very high accuracy and specificity for detecting ovarian cancer.
News Tesaro's Zejula primed for EU approval, battle with AZ EU regulators recommend PARP inhibitor Zejula
News Rubraca outshines rivals in ovarian cancer maintenance thera... Clovis' Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
News FDA starts speedy review of Imfinzi in bladder cancer AstraZeneca is closing on FDA approval of a new bladder cancer indication for Imfinzi that could help to fend off encroachment from MSD's Keytruda.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
